WHO ARE WE?

- We are a group of scientists who study hereditary breast cancer
- Our research focuses on the prevention and treatment of breast cancer in women with a genetic mutation
- We have studied the treatment of breast cancer in women with a BRCA1 or BRCA2 mutation and how treatment can be personalized for these women
- We now want to understand if we should also personalize treatment for women with a PALB2 mutation who develop breast cancer
- This study is a collaboration between Women’s College Hospital in Toronto (Drs. Kelly Metcalfe and Steven Narod) and the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee (Dr. Tuya Pal)

“I had negative BRCA testing several years ago, but my strong family history of breast cancer led my breast surgeon to offer me additional genetic testing for several other inherited breast cancer genes (called multi-gene panel testing) once it became available. Through this testing, I was found to carry a PALB2 gene mutation. I have since enrolled in the Inherited Cancer Registry, as I am interested in participating in research in any way that I can to learn more about inherited cancers in people with a PALB2 mutation.”

Mari-Lynn Slayton, two-time breast cancer survivor and carrier of a PALB2 mutation

FOR MORE INFORMATION ABOUT THIS RESEARCH STUDY, PLEASE CONTACT

OUR STUDY TEAM:

United States: (615) 875-2444
Canada: (416) 351-3800 x2761
Email: ICARE@InheritedCancer.net
Website: InheritedCancer.net/palb2-study

RESOURCES

Inherited Cancer Registry (ICARE)
ICARE’s mission is to end the cycle of inherited cancer through research, education, and outreach. Through ICARE, we partner with healthcare providers and patients facing inherited cancer risk to meet this goal. To learn more, visit InheritedCancer.net or contact the study team:

Email: ICARE@InheritedCancer.net
Phone: (615) 875-2444

National Society of Genetic Counselors
To locate a genetic counselor near you, please visit: www.NSGC.org
A mutation in the **PALB2** gene raises the risk for developing certain types of cancer

- For women with a **PALB2** mutation, the lifetime risk of breast cancer is ~35-40% compared to 12% for women in the general population
- There may be other increased cancer risks, including pancreatic cancer and male breast cancer

Why is it important to learn more about breast cancers that occur in women with a **PALB2** mutation?

Currently, we know little about breast cancers that occur in women with a **PALB2** mutation. Thus, it is important:

- To learn how to best treat women with a **PALB2** mutation who develop breast cancer
- To determine how women with a **PALB2** mutation without breast cancer can best manage their cancer risks and be proactive about their health

**Who is eligible to participate in this study?**

- Women with a pathogenic or likely pathogenic **PALB2** mutation with or without a personal history of cancer

**What will I be asked to do?**

- Complete an informed consent form indicating your willingness to participate
- Complete a baseline questionnaire, either on paper or online
- Complete a medical record release so the study team can collect information on genetic test results, and breast cancer pathology and treatment
- Agree to be contacted every two years to update your information

United States: (615) 875-2444  
Canada: (416) 351-3800 x2761  
Email: ICARE@InheritedCancer.net  
Website: [InheritedCancer.net/palb2-study](http://InheritedCancer.net/palb2-study)

**Our Mission**

To determine the best treatment for women with a **PALB2** mutation and breast cancer.

Through a better understanding, we can personalize breast cancer treatment to increase survival, and determine how to best manage at risk family members to detect cancer early or prevent it.

**Why is your participation important?**

Learning more about breast cancer among women with a **PALB2** mutation will help to better understand:

- If women with breast cancer have an increased risk of developing a new breast cancer
- The best treatment for women with a **PALB2** mutation and breast cancer to increase the chance of survival
- How healthy family members who carry a **PALB2** mutation can best manage their cancer risks (through screening or preventive surgery, etc.)